» Articles » PMID: 36480493

Triggering of Lymphocytes by CD28, 4-1BB, and PD-1 Checkpoints to Enhance the Immune Response Capacities

Overview
Journal PLoS One
Date 2022 Dec 8
PMID 36480493
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor infiltrating lymphocytes (TILs) usually become exhausted and dysfunctional owing to chronic contact with tumor cells and overexpression of multiple inhibitor receptors. Activation of TILs by targeting the inhibitory and stimulatory checkpoints has emerged as one of the most promising immunotherapy prospectively. We investigated whether triggering of CD28, 4-1BB, and PD-1 checkpoints simultaneously or alone could enhance the immune response capacity of lymphocytes. In this regard, anti-PD-1, CD80-Fc, and 4-1BBL-Fc proteins were designed and produced in CHO-K1 cells as an expression host. Following confirmation of the Fc fusion proteins' ability to bind to native targets expressed on engineered CHO-K1 cells (CHO-K1/hPD-1, CHO-K1/hCD28, CHO-K1/hCTLA4, and CHO-K1/h4-1BB), the effects of each protein, on its own and in various combinations, were assessed in vitro on T cell proliferation, cytotoxicity, and cytokines secretion using the Mixed lymphocyte reaction (MLR) assay, 7-AAD/CFSE cell-mediated cytotoxicity assay, and a LEGENDplex™ Human Th Cytokine Panel, respectively. MLR results demonstrated that T cell proliferation in the presence of the combinations of anti-PD-1/CD80-Fc, CD80-Fc/4-1BBL-Fc, and anti-PD-1/CD80-Fc/4-1BBL-Fc proteins was significantly higher than in the untreated condition (1.83-, 1.91-, and 2.02-fold respectively). Furthermore, anti-PD-1 (17%), 4-1BBL-Fc (19.2%), anti-PD-1/CD80-Fc (18.6%), anti-PD-1/4-1BBL-Fc (21%), CD80-Fc/4-1BBL-Fc (18.5%), and anti-PD-1/CD80-Fc/4-1BBL-Fc (17.3%) significantly enhanced cytotoxicity activity compared to untreated condition (7.8%). However, concerning the cytokine production, CD80-Fc and 4-1BBL-Fc alone or in combination significantly increased the secretion of IFN-γ, TNF-α, and IL-2 compared with the untreated conditions. In conclusion, this research establishes that the various combinations of produced anti-PD-1, CD80-Fc, and 4-1BBL-Fc proteins can noticeably induce the immune response in vitro. Each of these combinations may be effective in killing or destroying cancer cells depending on the type and stage of cancer.

Citing Articles

The roles and molecular mechanisms of non-coding RNA in cancer metabolic reprogramming.

Li S, Peng M, Tan S, Oyang L, Lin J, Xia L Cancer Cell Int. 2024; 24(1):37.

PMID: 38238756 PMC: 10795359. DOI: 10.1186/s12935-023-03186-0.


Regulating the regulatory T cells as cell therapies in autoimmunity and cancer.

Hosseinalizadeh H, Rabiee F, Eghbalifard N, Rajabi H, Klionsky D, Rezaee A Front Med (Lausanne). 2023; 10:1244298.

PMID: 37828948 PMC: 10565010. DOI: 10.3389/fmed.2023.1244298.

References
1.
Ramezani A, Mahmoudi Maymand E, Yazdanpanah-Samani M, Hosseini A, Toghraie F, Ghaderi A . Improving Pertuzumab production by gene optimization and proper signal peptide selection. Protein Expr Purif. 2017; 135:24-32. DOI: 10.1016/j.pep.2017.04.013. View

2.
Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J . PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009; 21(9):1065-77. PMC: 2731790. DOI: 10.1093/intimm/dxp072. View

3.
Chae Y, Arya A, Iams W, Cruz M, Chandra S, Choi J . Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018; 6(1):39. PMC: 5956851. DOI: 10.1186/s40425-018-0349-3. View

4.
Qiao Y, Qiu Y, Ding J, Luo N, Wang H, Ling X . Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity. Nat Commun. 2021; 12(1):6360. PMC: 8569200. DOI: 10.1038/s41467-021-26645-6. View

5.
Segal N, Logan T, Hodi F, McDermott D, Melero I, Hamid O . Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clin Cancer Res. 2016; 23(8):1929-1936. DOI: 10.1158/1078-0432.CCR-16-1272. View